Case Control Study
Copyright ©The Author(s) 2019.
World J Gastrointest Oncol. Dec 15, 2019; 11(12): 1126-1140
Published online Dec 15, 2019. doi: 10.4251/wjgo.v11.i12.1126
Table 2 Protein plasma expression in adenocarcinoma patients and interaction with clinical and biological parameters, n (%)
Protein expressionMidkine
Activin
Low (n = 60)High (n = 54)Low (n = 42)High (n = 72)
Age (yr), mean (SD)63.02 (10.06)66.7 (10.91)63.64 (10.4)65.42 (10.7)
BMI (kg/m2), median (IQR)24.34 (20.71-26.54)25.79 (23.11-27.52)a25.66 (22.24-27.52)24.52 (22.05-26.94)
CA 19-9 (U/mL), median (IQR)400 (53.5-400)352 (70-400)400 (53.5-400)191 (70-400)
Age > 50 yr53 (88.33)50 (92.59)36 (85.71)67 (93.06)
Sex (female)27 (45)20 (37.04)18 (42.86)29 (40.28)
Stage (III-IV vs I-II)28 (46.67)39 (72.22)b20 (47.62)47 (65.28)
Histological grade
G13 (16.67)4 (17.39)3 (16.67)4 (17.39)
G210 (55.56)12 (52.17)13 (72.22)9 (39.13)
G35 (27.78)7 (30.43)2 (11.11)10 (43.48)
Metastasis20 (33.33)28 (51.85)a14 (33.33)34 (47.22)
Tumor size ≥ 3 cm44 (78.57)43 (87.76)30 (75)57 (87.69)
Weight loss of 5% over the past 6 mo45 (90)29 (82.86)11 (26)23 (32)
Weight
Underweight9 (15)3 (5.56)3 (7.14)9 (12.5)
Normal28 (46.67)20 (37.04)16 (38.1)32 (44.44)
Overweight15 (25)22 (40.74)14 (33.33)23 (31.94)
Obesity8 (13.33)9 (16.67)8 (11.11)
Smoking32 (53.33)18 (33.33)a17 (40.48)33 (45.83)
New-onset diabetes16 (26.67)8 (14.81)8 (19.05)16 (22.22)
Long-term diabetes6 (10)18 (33.33)b10 (23.81)14 (19.44)
Diabetes22 (36.67)27 (50)18 (42.86)31 (43.06)
IHC
Negative36 (60)22 (40.74)a29 (69.05)26 (36.11)b
Weak18 (30)16 (29.63)11 (26.19)42 (58.33)
Moderate5 (8.33)11 (20.37)2 (4.76)4 (5.56)
Strong1 (1.67)5 (9.26)
Immunohistochemistry perineural invasion (appearances on slide)2: 3 (9.09); 0: 17 (51.52); 1: 13 (39.39)2: 9 (32.14)a; 0: 7 (25); 1: 12 (42.86)2: 5 (17.86); 0: 13 (46.43); 1: 10 (35.71)2: 7 (21.21); 0: 11 (33.33); 1: 15 (45.45)
Cachexia16 (73)6 (27)15 (26)7 (32)